The Cost-Effectiveness of Nivolumab for The Treatment of People with Relapsed or Refractory Classical Hodgkin Lymphoma Following Autologous Stem Cell Transplant and Brentuximab Vedotin
Abstract
Authors
B Jones T Ward JP Harrison M Hurst D Tyas P McEwan J Gordon